Your Cart is Empty
Start shopping
MOUNJARO®
MOUNJARO® 12.5mg KwikPen®, 1 Stk.
Note: Actual packaging may vary.
MOUNJARO® 12.5mg KwikPen®, 1 Stk.
| Quantity | Discount (%) | Price |
|---|---|---|
| 1 - 3 | — | $579.00 |
| 4 - 10 | 8.64 % | $529.00 |
| 11 - 20 | 9.5 % | $524.00 |
| 21+ | 10.36 % | $519.00 |
The 12.5 mg dose is an intermediate escalation step in the tirzepatide titration schedule, following the 10 mg level when additional dose advancement is indicated. MOUNJARO® 12.5 mg KwikPen® is administered once weekly by subcutaneous injection, at any time of day, with or without food. Injection sites are the abdomen, thigh, or — when another person administers the dose — the back of the upper arm. Sites should be rotated with each dose.
Tirzepatide titration begins at 2.5 mg once weekly for 4 weeks, then increases to 5 mg. If additional glycemic response is needed, the dose may be increased by 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg once weekly.
If a dose is missed, it may be administered within 4 days (96 hours) of the scheduled date. If more than 4 days have passed, skip the missed dose and resume the regular weekly schedule. When using MOUNJARO® with insulin, administer as separate injections and never mix. Both injections may be given in the same body region but not adjacent to each other. For information on other MOUNJARO® KwikPen® doses, contact the Med Supply Solutions team.
MOUNJARO® (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. In pediatric patients, the maximum recommended dose is 10 mg once weekly. Use should be interpreted in accordance with current local prescribing information.
Tirzepatide is the active ingredient in two distinct branded products: MOUNJARO® is indicated for type 2 diabetes, and Zepbound® is indicated for chronic weight management. These products carry separate regulatory approvals and are not interchangeable.
MOUNJARO® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with a documented serious hypersensitivity reaction to tirzepatide or any excipient in the formulation. MOUNJARO® is not indicated for patients under 10 years of age.
MOUNJARO® 12.5 mg KwikPen® is supplied as 50 mg/2.4 mL, providing four 12.5 mg/0.6 mL doses per single-patient-use pen. The formulation is a clear, colorless-to-slightly-yellow sterile solution. Excipients include benzyl alcohol, glycerin, and phenol, among others listed in the full prescribing information; benzyl alcohol content is relevant to the multi-dose pen format.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite and energy intake.
Store refrigerated at 2–8°C (36–46°F) and protect from light. If removed from refrigeration, the pen may be kept at room temperature up to 30°C (86°F) for up to 21 days. Do not freeze.
Clinical trial context: In the SURMOUNT-1 trial, participants in the 15 mg tirzepatide arm — an obesity study in patients without type 2 diabetes — achieved a mean body weight reduction of approximately 21% at 72 weeks. This result is specific to the 15 mg dose in that trial population and is not an expected outcome for the 12.5 mg escalation dose.
Before each injection, inspect the solution: it should be clear and colorless to slightly yellow. Do not use the pen if the solution is cloudy, discolored, or contains visible particles.
Attach a new needle to the KwikPen® immediately before use. Needles must not be reused. Inject subcutaneously into the abdomen, thigh, or — when another person is administering — the back of the upper arm. Rotate the injection site with each weekly dose. After injection, remove the needle without recapping and discard it in an approved sharps container.
Store the pen in the refrigerator at 2–8°C between uses. If removed from refrigeration, keep at room temperature up to 30°C for up to 21 days. Protect from light. Do not freeze.
Prescribers and dispensing professionals should confirm that patients and caregivers have been trained on the manufacturer’s Instructions for Use and the package leaflet prior to first administration.
The 12.5 mg dose is an intermediate escalation step in the tirzepatide titration schedule, following the 10 mg level when additional dose advancement is indicated. MOUNJARO® 12.5 mg KwikPen® is administered once weekly by subcutaneous injection, at any time of day, with or without food. Injection sites are the abdomen, thigh, or — when another person administers the dose — the back of the upper arm. Sites should be rotated with each dose.
Tirzepatide titration begins at 2.5 mg once weekly for 4 weeks, then increases to 5 mg. If additional glycemic response is needed, the dose may be increased by 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg once weekly.
If a dose is missed, it may be administered within 4 days (96 hours) of the scheduled date. If more than 4 days have passed, skip the missed dose and resume the regular weekly schedule. When using MOUNJARO® with insulin, administer as separate injections and never mix. Both injections may be given in the same body region but not adjacent to each other. For information on other MOUNJARO® KwikPen® doses, contact the Med Supply Solutions team.
MOUNJARO® (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. In pediatric patients, the maximum recommended dose is 10 mg once weekly. Use should be interpreted in accordance with current local prescribing information.
Tirzepatide is the active ingredient in two distinct branded products: MOUNJARO® is indicated for type 2 diabetes, and Zepbound® is indicated for chronic weight management. These products carry separate regulatory approvals and are not interchangeable.
MOUNJARO® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with a documented serious hypersensitivity reaction to tirzepatide or any excipient in the formulation. MOUNJARO® is not indicated for patients under 10 years of age.
MOUNJARO® 12.5 mg KwikPen® is supplied as 50 mg/2.4 mL, providing four 12.5 mg/0.6 mL doses per single-patient-use pen. The formulation is a clear, colorless-to-slightly-yellow sterile solution. Excipients include benzyl alcohol, glycerin, and phenol, among others listed in the full prescribing information; benzyl alcohol content is relevant to the multi-dose pen format.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite and energy intake.
Store refrigerated at 2–8°C (36–46°F) and protect from light. If removed from refrigeration, the pen may be kept at room temperature up to 30°C (86°F) for up to 21 days. Do not freeze.
Clinical trial context: In the SURMOUNT-1 trial, participants in the 15 mg tirzepatide arm — an obesity study in patients without type 2 diabetes — achieved a mean body weight reduction of approximately 21% at 72 weeks. This result is specific to the 15 mg dose in that trial population and is not an expected outcome for the 12.5 mg escalation dose.
Before each injection, inspect the solution: it should be clear and colorless to slightly yellow. Do not use the pen if the solution is cloudy, discolored, or contains visible particles.
Attach a new needle to the KwikPen® immediately before use. Needles must not be reused. Inject subcutaneously into the abdomen, thigh, or — when another person is administering — the back of the upper arm. Rotate the injection site with each weekly dose. After injection, remove the needle without recapping and discard it in an approved sharps container.
Store the pen in the refrigerator at 2–8°C between uses. If removed from refrigeration, keep at room temperature up to 30°C for up to 21 days. Protect from light. Do not freeze.
Prescribers and dispensing professionals should confirm that patients and caregivers have been trained on the manufacturer’s Instructions for Use and the package leaflet prior to first administration.
Frequently Bought Together
About the product
Positioned as the final escalation step before the 15 mg ceiling, the 12.5 mg strength bridges the 10 mg maintenance level and the highest available dose in the tirzepatide schedule. MOUNJARO® 12.5 mg KwikPen® delivers tirzepatide 12.5 mg per 0.6 mL as a once-weekly subcutaneous GIP/GLP-1 receptor agonist manufactured by Eli Lilly, supplied as a 1 pc. pack with one KwikPen® containing four doses. For related products in this category, browse tirzepatide weight management products. To buy MOUNJARO® 12.5 mg online, contact the Med Supply Solutions team.